Clinical trials: Clopidogrel Resistance
Platelet Reactivity
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01463150
- Testing
- Clopidogrel, Prasugrel
- Where
- Greece
- Volunteers
- 27 people
- Sponsor
- University of Patras
Coronary Artery Disease
Clopidogrel Resistance and the Possibility of Its Affection
The purpose of the study is to determine, whether the resistance to clopidogrel could be affected by higher doses of this drug, or by replacement of clopidogrel with another ADP-antagonist ticlopidine.
- Trial name
- NCT00839345
- Testing
- clopidogrel
- Where
- Czechia
- Sponsor
- Charles University, Czech Republic
Angioplasty
Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous…
- Trial name
- NCT00289601
- Testing
- eptifibatide
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Graft Patency, Coronary Artery Bypass Grafting Surgery
ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
The purpose of this study is to determine whether adding clopidogrel to aspirin after coronary bypass operation (CABG) improves graft patency, in patients that have preoperatively increased platelet activity(hypercoagulable) and…
- Conditions
- Graft Patency, Coronary Artery Bypass Grafting Surgery, Hypercoagulability, Thrombosis
- Trial name
- TEG-CABG (NCT01046942)
- Testing
- Clopidogrel+acetylsalicylic acid, acetylsalicylic acid
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Coronary Syndromes, Percutaneous Coronary Intervention
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests.
- Conditions
- Acute Coronary Syndromes, Percutaneous Coronary Intervention, Clopidogrel Low Responsiveness
- Trial name
- NCT01094457
- Testing
- aspirin, clopidogrel, aspirin, clopidogrel, cilostazol
- Where
- 3 sites in China
- Volunteers
- 840 people
- Sponsor
- Shenyang Northern Hospital
Coronary Heart Disease
Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR
Coronary microvascular dysfunction (CMD) is increasingly recognized as an important indicator for long-term prognosis in patients with acute myocardial infarction (AMI).
- Trial name
- NCT05978726
- Testing
- Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.
- Trial name
- BOCLAplan (NCT01212302)
- Testing
- Optimizing ASA and clopidogrel treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ruhr University of Bochum
Cardiovascular Disease
Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients
The investigators are trying to find out if Clopidogrel (Plavix) is as effective in hemodialysis patients as in patients not hemodialysed.
- Trial name
- NCT01865890
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
Coronary Artery Disease, Atherosclerosis
Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)
The risk of thrombotic complications after implantation of drug-eluting stents (DES) may be increased in patients with diabetes mellitus (DM) or metabolic syndrome (MS).
- Conditions
- Coronary Artery Disease, Atherosclerosis, Diabetes Mellitus, Metabolic Syndrome X
- Trial name
- SPACE (NCT00298428)
- Testing
- blood samples
- Where
- 2 sites in France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atherosclerosis, Angioplasty
Resistance to Antithrombotic Therapy
Clopidogrel plays a pivotal role in the antithrombotic regimen after percutaneous intervention with stent implantation. However, response to clopidogrel shows a wide interindividual variability and a high on-treatment residual…
- Trial name
- Vienna REACT (NCT00858715)
- Testing
- aspirin, clopidogrel
- Where
- Austria
- Volunteers
- 46 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease
Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents
It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year.
- Trial name
- NCT00589862
- Testing
- Plavix (Clopidogrel)
- Where
- United States
- Sponsor
- Creighton University
Clopidogrel Non-Responsiveness
Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS
Laboratory clopidogrel resistance is associated with adverse atherothrombotic events in patients with coronary artery disease. In the proposed study we wish to prospectively assess the effect of reloading with 600 mg clopidogrel…
- Trial name
- NCT00444132
- Testing
- clopidogrel
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Platelet Dysfunction
clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
The aim of this study was to determine the prevalence of clopidogrel resistance among a selected group of patients undergoing elective percutaneous coronary intervention and to observe whether there was any south-Asian…
- Trial name
- POINT (NCT03667066)
- Testing
- Clopidogrel
- Where
- Trinidad and Tobago
- Volunteers
- 40 people
- Sponsor
- The University of The West Indies
Clopidogrel, Poor Metabolism of, Ischemic Stroke
Clopidogrel Resistance in Stroke Patients From Different Ethnicities
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events.
- Trial name
- NCT03806894
- Testing
- Quantification of platelet aggregation
- Volunteers
- 300 people
- Sponsor
- Ziv Hospital
Non-ST Segment Elevation Myocardial Infarction, ST Segment Elevation Myocardial Infarction
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than clopidogrel and is associated with less interindividual variability.
- Trial name
- NCT02026219
- Testing
- Clopidogrel, Ticagrelor
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Inha University Hospital
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Ischemic Cerebrovascular Disease
Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance
1. Clopidogrel resistance is common in patients of ischemic cerebrovascular disease. 2. Genetic polymorphisms are the most important factors to clopidogrel resistance. 3.
- Trial name
- ORETCR (NCT01925872)
- Volunteers
- 2,000 people
- Sponsor
- Zhongrong Miao